Adjuvant Nivolumab: New Standard of Care for Melanoma? Adjuvant Nivolumab: New Standard of Care for Melanoma?

In resected melanoma, nivolumab improves recurrence-free survival with less toxicity. Dr Jeffrey Weber discusses results of the CheckMate 238 study presented at ESMO 2017Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news